Edition:
United Kingdom

CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

27.18USD
16 Jan 2018
Change (% chg)

$-1.34 (-4.70%)
Prev Close
$28.52
Open
$28.24
Day's High
$28.79
Day's Low
$26.50
Volume
246,022
Avg. Vol
108,967
52-wk High
$30.66
52-wk Low
$11.74

Chart for

About

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct... (more)

Overall

Beta: --
Market Cap(Mil.): $1,308.81
Shares Outstanding(Mil.): 45.89
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 207.59 16.63
EPS (TTM): -- -- --
ROI: -- -11.19 33.78
ROE: -- -33.91 17.31

BRIEF-Crispr Therapeutics Says Public Offering Of 5 Mln Common Shares Priced At $22.75/Share

* CRISPR THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES

05 Jan 2018

BRIEF-Crispr Therapeutics ‍Commences Public Offering Of $100 Mln Common Shares​

* CRISPR THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES

03 Jan 2018

BRIEF-Vertex, CRISPR Therapeutics To Co-Develop CTX001 As CRISPR/Cas9 Gene Edited Treatment

* VERTEX AND CRISPR THERAPEUTICS TO CO-DEVELOP AND CO-COMMERCIALIZE CTX001 AS CRISPR/CAS9 GENE EDITED TREATMENT FOR SICKLE CELL DISEASE AND Β-THALASSEMIA

12 Dec 2017

BRIEF-CRISPR Therapeutics appoints Michael Tomsicek as CFO

* CRISPR Therapeutics announces appointment of Michael Tomsicek as Chief Financial Officer

13 Nov 2017

BRIEF-CRISPR and Casebia collaborate with CureVac on mRNA for gene-editing programs

* CRISPR Therapeutics and Casebia collaborate with CureVac on mRNA for gene-editing programs

13 Nov 2017

BRIEF-Crispr Therapeutics files for mixed shelf offering of up to $300 mln - SEC filing‍​

* Crispr Therapeutics AG - files for mixed shelf offering of up to $300 million - SEC filing‍​ Source text: (http://bit.ly/2jeQFaT) Further company coverage:

09 Nov 2017

BRIEF-CRISPR Therapeutics announces third quarter results

* CRISPR Therapeutics announces third quarter 2017 financial results and provides business update

08 Nov 2017

BRIEF-Merck KGaA: Canadian patent office to grant patent application for CRISPR technology

* MERCK KGAA - CANADIAN PATENT OFFICE TO GRANT MERCK KGAA, DARMSTADT, GERMANY'S PATENT APPLICATION FOR CRISPR TECHNOLOGY

24 Oct 2017

BRIEF-CRISPR Therapeutics promotes Samarth Kulkarni to CEO

* CRISPR Therapeutics announces promotion of Samarth Kulkarni, Ph.D. to chief executive officer

02 Oct 2017

BRIEF-Crispr Therapeutics Ag qtrly ‍net loss per share attributable to common shareholders $0.56​

* Crispr Therapeutics announces second quarter 2017 financial results and provides business update

10 Aug 2017

Earnings vs. Estimates